New drug duo aims to stop lung cancer in its tracks
NCT ID NCT06322108
First seen Jun 09, 2026 · Last updated Jun 15, 2026 · Updated 2 times
Summary
This study tests whether two immunotherapy drugs, balstilimab and botensilimab, can safely control advanced non-small cell lung cancer. About 45 people who have not had prior treatment for metastatic disease will receive the combination. The main goal is to see how many patients remain cancer-free or stable after 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Center named after prof. R. Yeolyan
Yerevan, 0014, Armenia
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.